Ishihara Sangyo Kaisha, Ltd.   Report issue

For profit Phase 2
Founded: Osaka Japan (1920)
Status: No NME R&D (1920)

Organization Overview

First Clinical Trial
2019
NCT03818893
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

ISHIHARA SANGYO KAISHA,LTD. Japan

Active Ingredients

Drugs in Phase 2 Trials (2)

gen0101 (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Melanoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2